SK pharmteco and Prozomix Partner to Strengthen Biocatalysis in Drug Manufacturing
Wednesday, March 25, 2026
SK pharmteco and Prozomix have announced a strategic collaboration to advance biocatalysis capabilities in global drug manufacturing.
The partnership will integrate Prozomix’s enzyme libraries into SK pharmteco’s small molecule development and manufacturing services, aiming to support more efficient and sustainable pharmaceutical processes.
Under the agreement, SK pharmteco will gain access to Prozomix’s Biocatalysis Enzyme Toolkit, which includes more than 6,000 native biocatalysts. These enzymes will be used across SK pharmteco’s research and development sites in the United States, Europe, and Asia to identify suitable enzymes for complex active pharmaceutical ingredient (API) synthesis.
The collaboration is expected to support the growing demand for greener and more cost-effective manufacturing methods. Enzyme-based processes can offer improved selectivity and reduced environmental impact compared to traditional chemical synthesis, particularly as drug molecules become more complex.
By combining SK pharmteco’s expertise in API production with Prozomix’s enzyme capabilities, the partnership aims to provide a streamlined path from early-stage enzyme screening to large-scale manufacturing. This approach is intended to reduce development timelines and improve process efficiency.
Prozomix’s experience in early-stage bioprocess development and enzyme scale-up will be extended to a wider range of pharmaceutical projects through SK pharmteco’s global manufacturing network. The collaboration is also expected to enhance access to advanced biocatalysis solutions for clients across different regions.
Overall, the agreement expands SK pharmteco’s technology portfolio and strengthens its position as a multi-modality partner within the global biopharmaceutical sector.
Source: skpharmteco.com
